ODM derived from



  1. 19/03/2013 19/03/2013 - Martin Dugas
  2. 19/04/2014 19/04/2014 - Julian Varghese
  3. 20/09/2021 20/09/2021 -
Téléchargé le

20 septembre 2021


Pour une demande vous connecter.


Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility NCT01194219 Plaque Psoriasis


  1. StudyEvent: Eligibility
    1. Eligibility
Alter mindestens 18 Jahre
Males or females, ≥ 18 years of age at the time of signing the informed consent document
Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening
Have moderate to severe plaque psoriasis at Screening and Baseline
Must meet all laboratory criteria
Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception as described by the Study Doctor while on study medication and for at least 28 days after taking the last dose of study medication
Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane]) while on study medication and for a least 28 days after the last dose of study medication.
Other than psoriasis, history of any clinically significant (as determined by the Investigator) or other major uncontrolled disease.
Pregnant or breast feeding
History of allergy to any component of the study drug
Hepatitis B surface antigen positive at Screening
Anti-hepatitis C antibody positive at Screening
Active tuberculosis (TB) or a history of incompletely treated TB
Clinically significant abnormality on 12-Lead ECG at Screening
Clinically significant abnormal chest x-ray
History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency
Active substance abuse or a history of substance abuse within 6 months prior to Screening
Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening
Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years)
Psoriasis flare or rebound within 4 weeks prior to Screening
Evidence of skin conditions that would interfere with clinical assessments
Topical therapy within 2 weeks of randomization
Systemic therapy for psoriasis within 4 weeks prior to randomization
Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)
Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization
Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization
Use of any investigational drug within 4 weeks prior to randomization
Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
Prior treatment with apremilast

Similar models

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial